{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.809","pValueComment":"Two-sided p-value.","statisticalMethod":"0.809"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9"},{"groupId":"OG001","value":"1.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"61"}],"units":"Participants"}],"description":"Incident events are defined as having penile/scrotal warts reported clinically in participants penile/scrotal condyloma at baseline.","groups":[{"description":"HPV 11 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.","id":"OG000","title":"Naive to HPV 11"},{"description":"HPV 11 positive based on serum at visit 0.","id":"OG001","title":"Prior Exposure to HPV 11"}],"paramType":"NUMBER","populationDescription":"Eligible participants without penile/scrotal condyloma at baseline who received at least one vaccination and returned after month 7 with evaluable clinical assessments.","reportingStatus":"POSTED","timeFrame":"Post month 7 through month 24","title":"Incidence of Penile/Scrotal Condyloma in HPV 11 Naive and Prior Exposed Participants","type":"PRIMARY","unitOfMeasure":"per 100 person years"}